Please do not spread wrong information on this very good company. The truth is good enough to make this stock move higher.
There is only 1 product ARX-01 that is heading for NDA submission in 3Q2013 after successful completion of the additional 2 ongoing phase 3 trials. Results of those 2 trials are expected 1Q2013.
2 other products have successfully completed phase 2 and are ready to move into phase 3.
1 other product just started phase 2 and R&D is covered by US army grant.